Drug Profile
Research programme: endopeptidase Clp stimulants - Arietis Corporation
Alternative Names: Novo 23Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Arietis Corporation
- Class Cyclic peptides; Peptides
- Mechanism of Action Endopeptidase Clp stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Tuberculosis in USA
- 12 Sep 2012 Pharmacodynamics data from a preclinical trial in Tuberculosis presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)
- 01 Sep 2012 Preclinical trials in Tuberculosis in USA (unspecified route)